Venous Sclerosants: Cardiovascular Adverse Effects and Misuse
GCM team
May 7, 2026
No Comments
Key Overview • Study Basis: In France, the marketed venous sclerosants are Aetoxisclerol (the
Does Eliminating Reflux Always Require Ablating the Great Saphenous Vein?
GCM team
May 7, 2026
No Comments
Key Points • Study basis: In 2001, Paolo Zamboni and colleagues published a study
What Makes CHIVA Difficult Is Not the Procedure Alone
GCM team
April 28, 2026
No Comments
Key Points Study basis: In 2024, Stefano Ricci published CHIVA for dummies in Phlebology,
When the Main Deep Venous Pathway Is Closed, the Great Saphenous Vein May Become the Last Compensatory Channel
GCM team
April 27, 2026
No Comments
Key Points Study basis: A 2026 case report published in Case Reports in Cardiology
What Happens to Ulcer Outcomes in PTS Patients When the Great Saphenous Vein Is Missing?
GCM team
April 17, 2026
No Comments
Key Points •Study basis: A 2024 retrospective comparative study published in the Journal of
CHIVA Is Entering a More Organized Phase of Global Expansion
GCM team
April 15, 2026
No Comments
Key Points Program basis: APCA describes the Global CHIVA Program as a global education,
A 2025 Review Offers a Longer-Term Perspective: The Value of Preserving the Great Saphenous Vein in CHIVA Goes Beyond Being Minimally Invasive
GCM team
April 10, 2026
No Comments
Key Points Study basis: In 2025, Hidayet Tarik Kiziltan, Stefano Ermini, and Claude Franceschi
From “Removal” to “Correction”: A 2023 Review Re-emphasizes the True Positioning of CHIVA
GCM team
April 9, 2026
No Comments
Key Points • Article background: In 2023, Roberto Delfrate published a review in the
Recent Post
